Stomach Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032



Stomach cancer, also known as gastric cancer, is a malignancy that originates from the stomach lining. It is a slow-growing cancer and is considered a multifactorial disease. The International Agency for Research on Cancer (IARC) has classified the bacterium Helicobacter pylori (H. pylori) as a carcinogen in humans due to the evidence linking H. pylori infection and an increased risk of gastric cancer. The mechanism by which H. pylori acts as a carcinogen is believed to be indirect, through the induction of gastritis, which can lead to the development of precancerous conditions such as gastric atrophy, metaplasia, and dysplasia. Individuals with certain genetic disorders, such as hereditary diffuse gastric cancer, Peutz-Jeghers syndrome, and familial adenomatous polyposis, have an increased risk of developing stomach cancer. Mutations or deletions in genes such as p53, BRCA2, MSH2, and MLH1 also increase the risk of gastric cancer. The symptoms of stomach cancer can be classified into two stages: early stage and advanced stage. The most common type of stomach cancer is adenocarcinoma, which accounts for approximately 90% of all cases. Other types of stomach cancer include gastric lymphomas, gastrointestinal stromal tumors, and carcinoid tumors. The risk factors for developing stomach cancer include age, gender, H. pylori infection, family history/genetics, race/ethnicity, diet, previous surgery or health conditions, occupational exposure, tobacco and alcohol use, and obesity. The five-year survival rate for individuals diagnosed with stomach cancer is 31.2%.

·       The estimated incidence of stomach cancer in the USA is 5.6 per 100,000 individuals.

Thelansis’s “Stomach Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Stomach Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Stomach Cancer across 8 MM market from the Centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Stomach Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Stomach Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033